App-Quantinova.ai

A Phase lb Dose Escalation Study of the OX40 Agonist MOXR0916 and the PD-L1 Inhibitor Atezolizumab in Patients with Advanced Solid Tumors

Jeffrey R. Infante - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Atezolizumab

ETNA (Evaluating Treatment with Neoadjuvant Abraxane) Randomized Phase III Study Comparing Neoadjuvant Nab-Paclitaxel (nab-P) Versus Paclitaxel (P) Both Followed by Anthracycline Regimens in Women with HER2-Negative High-Risk Breast Cancer: A MICHELANGO Study in collaboration with GEICAM and BCRC-WA

Luca Gianni - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Paclitaxel

Efficacy of palbociclib plus fulvestrant (P+F) in patients (pts) with metastatic breast cancer (MBC) and ESR1 mutations (mus) in circulating tumor DNA (ctDNA).

Nicholas C. Turner - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Fulvestrant

Palbociclib (PAL) in combination with fulvestrant (F) in pre-/peri-menopausal (PreM) women with metastatic breast cancer (MBC) and prior progression on endocrine therapy results from Paloma-3.

Sibylle Loibl - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Fulvestrant

Simplified CYP2D6 metabolizer phenotype categorization of patients treated with tamoxifen: Role for endoxifen level monitoring?

Clara Inkyung Lee - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

endoxifen

Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+), HER2-negative (HER2) advanced breast cancer (aBC): Phase Ib safety, preliminary efficacy and molecular analysis.

Dejan Juric - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Ribociclib

Effect of progesterone receptor on outcome of women with breast cancer.

Shaheenah S. Dawood - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Tumor infiltrating lymphocytes and hydrophobic amino acid changes in HER2-positive metastatic breast cancer.

Vassiliki Kotoula - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Trastuzumab

The association of surgical margins and local recurrence in women with ductal carcinoma in situ treated with breast-conserving therapy: A meta-analysis.

Michael Luke Marinovich - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Cardiovascular disease incidence and mortality in breast cancer survivors compared to the general population: Systematic review and meta-analysis.

Marina Michelle Reeves - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Prognostic utility of tumour infiltrating lymphocytes (TILs) and neutrophil-to-lymphocyte ratio (NLR) in early-stage triple negative breast cancer (TNBC).

Antonia Pearson - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

N/A

Risk of uterine cancer in BRCA1 and BRCA2 mutation carriers.

Yeh Chen Lee - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Endometrial Cancer

N/A

Association of male breast cancer and prostate cancer: A large population based study.

Shaheenah S. Dawood - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

A pilot randomised controlled trial examining the feasibility, acceptability and impact of giving information on personalised genomic risk of melanoma to the public, for motivating preventive behaviours.

Anne E. Cust - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

N/A

Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors.

David Michael Hyman - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Alpelisib

A phase 1 study of CRLX301, a novel nanoparticle-drug conjugate (NDC) containing docetaxel (DOC), in patients with refractory solid tumors.

Ben Markman - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Docetaxel

Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM).

Martin J. Van Den Bent - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Temozolomide

Phase I/II dose-escalation and expansion study of afuresertib + carboplatin and paclitaxel in recurrent ovarian cancer.

Sarah Patricia Blagden - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gynaecological cancer

Afuresertib

Pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma: Phase 1 KEYNOTE-022 study.

Antoni Ribas - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

Pembrolizumab

A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors.

Jayesh Desai - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Tislelizumab

Filters

13968 Abstracts